Programa de Neuroimmunología - IDIBAPS

Qui som

Tornar
|Alt Image doctor|

Dr. Pablo Villoslada

Esclerosi Múltiple, Patogènesi i Noves Teràpies

Càrrecs actuals

  • Director of the MS pathogenesis and therapeutics Group, IDIBAPS
  • National Coordinator of the Spanish Network of Excellence in Multiple Sclerosis (REEM), Instituto de Salud Carlos III
  • Member of the Scientific Advisory Board of the International Society of Neuroimmunology
  • Member of the Scientific Advisory Board of Multiple Sclerosis in Focus from the International Federation MS Societies
  • Member of the editorial boards of PloSONE
  • Member of the American Academy of Neurology, International Society of Neuroimmunology, American Association for the Advancement of Science, Spanish Society of Neurology, Catalan Society of Neurology

Formació acadèmica

  • Degree in Medicine and Surgery from the University of Santiago Compostela, 1990
  • Doctorate of Neurosciences from the Autonomous University of Barcelona, 1996
  • Post-doctoral Fellowship in Neuro-immunology, University of California, San Francisco, USA, 1996-97
  • Post-doctoral Fellowship in clinical neuroimmunology, Vall Hebron Hospital, Barcelona, 1998-2000

Àrees de Recerca

Premis i mencions

  • Spanish Ministry of Health Postdoctoral Fellowship
  • Catalonian Research Foundation (FCR) Award
  • Spanish Multiple Sclerosis Foundation Award
  • Spanish Neurological Society Award for Biomedical Research in Demyelinating Diseases

Grants for Medical Research

  • Spanish Ministry of Health: Instituto de Salud Carlos III
  • TV3 Marathon Foundation, TV3, Catalonia, Spain
  • Spanish Ministry of Science and Technology
  • European Commission
  • Fundación Mutua of Madrid
  • Agency for the Administration of Universities and Research (AGAUR) of the Governement of Catalonia

Publicacions recents seleccionades

  • 1: Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A. Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler. 2012 Jul;18(7):991-9. Epub 2012 Jan 30. PubMed PMID: 22291035.
  • 2: Villoslada P, Baranzini S. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J Neuroimmunol. 2012 Jul 15;248(1-2):58-65. Epub 2012 Jan 24. Review. PubMed PMID: 22281286.
  • 3: Moreno B, Jukes JP, Vergara-Irigaray N, Errea O, Villoslada P, Perry VH, Newman TA. Systemic inflammation induces axon injury during brain inflammation. Ann Neurol. 2011 Dec;70(6):932-42. doi: 10.1002/ana.22550. PubMed PMID: 22190366.
  • 4: Vélez de Mendizábal N, Carneiro J, Solé RV, Goñi J, Bragard J, Martinez-Forero I, Martinez-Pasamar S, Sepulcre J, Torrealdea J, Bagnato F, Garcia-Ojalvo J, Villoslada P. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Syst Biol. 2011 Jul 15;5:114. PubMed PMID: 21762505; PubMed Central PMCID: PMC3155504.
  • 5: Bejarano B, Bianco M, Gonzalez-Moron D, Sepulcre J, Goñi J, Arcocha J, Soto O, Del Carro U, Comi G, Leocani L, Villoslada P. Computational classifiers for predicting the short-term course of Multiple sclerosis. BMC Neurol. 2011 Jun 7;11:67. PubMed PMID: 21649880; PubMed Central PMCID: PMC3118106.
  • 6: Villoslada P. Biomarkers for multiple sclerosis. Drug News Perspect. 2010 Nov;23(9):585-95. Review. PubMed PMID: 21152453.
  • 7: Moreno B, Fernandez-Diez B, Di Penta A, Villoslada P. Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Mult Scler. 2010 Sep;16(9):1102-8. Epub 2010 Jul 29. PubMed PMID: 20670985.
  • 8: Martínez-Forero I, Peláez-López A, Villoslada P. Steady state detection of chemical reaction networks using a simplified analytical method. PLoS One. 2010 Jun 3;5(6):e10823. PubMed PMID: 20532219; PubMed Central PMCID: PMC2880584.
  • 9: Tegnér JN, Compte A, Auffray C, An G, Cedersund G, Clermont G, Gutkin B, Oltvai ZN, Stephan KE, Thomas R, Villoslada P. Computational disease modeling - fact or fiction? BMC Syst Biol. 2009 Jun 4;3:56. PubMed PMID: 19497118; PubMed Central PMCID: PMC2697138.

Més publicacions Pubmed